In line with its status as a PBC, Trek is taking a notably creative approach to finding common ground with payers on pricing, profit and access. The lower price point made possible by this form of incorporation is viewed by the company as a competitive differentiator, one attractive enough to open the door to a more diverse customer base than is the case with traditional big pharma. Management is thinking long term, initiating dialogue with stakeholders – from the normal regulatory bodies to international organizations that contract for medicine supplies in bulk – much earlier than others in the HCV space. Likewise, it is breaking with traditional approaches to market access by considering financing models more commonly seen in adjacent businesses such as vaccines, insurance and consumer goods.
Leading the access effort is Trek’s VP for corporate and medical affairs, Cami Graham, MD, a practicing physician who also...